Summary of the II International Symposium on Cytomegalovirus

Menno D. De Jong, George J. Galasso, Brian Gazzard, Paul D. Griffiths, Douglas Jabs, Earl R. Kern, Stephen A. Spector

Research output: Contribution to journalReview article

Abstract

Human cytomegalovirus (HCMV) is a highly species-specific DNA virus belonging to the Betaherpesvirinae subfamily of the herpesviridae family. Like other herpesviruses, primary infection with HCMV is followed by persistence of the virus in a latent form. The sites of latency are still largely undefined, but they probably include bone marrow progenitor cells and peripheral blood monocytes. From these sites, the virus can reactivate, resulting in renewed shedding of the virus, or, in immunocompromized persons, development of disease. Humans are the only reservoir of HCMV and transmission occurs by person-to-person contact. Infection with HCMV is common. In most developed countries, HCMV seroprevalence steadily increases after infancy and 10-20% of children are infected before puberty. In adults, the prevalence of antibodies ranges from 40 to 100%. Although HCMV has a world-wide distribution, infection with HCMV is more common in the developing countries and in areas of low socioeconomic conditions, which is predominantly related to the closeness of contacts within these populations. Except for a mononucleosis-like illness in some persons, infection with HCMV rarely causes disease in immunocompetent individuals. However, HCMV can cause severe morbidity and mortality in congenitally infected newborns and immunocompromized patients, most notably transplant-recipients and HIV-infected persons. This article provides a review of the information presented at the Second International Symposium on Cytomegalovirus organized and convened by The Macrae Group (New York City, NY) in Acapulco, Mexico on 24-28 April 1998. During this symposium, the state-of-the-art knowledge on diagnosis, treatment and prophylaxis of HCMV infections were discussed, and, based on this information, attempts to highlight the future directions in basic and clinical research areas that need to be stimulated to facilitate advancement in prevention and treatment of CMV disease. Copyright (C) 1998 Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)141-162
Number of pages22
JournalAntiviral Research
Volume39
Issue number3
DOIs
StatePublished - Oct 1 1998

Fingerprint

Cytomegalovirus
Betaherpesvirinae
Infection
Viruses
Virus Shedding
Herpesviridae Infections
DNA Viruses
Herpesviridae
Seroepidemiologic Studies
Cytomegalovirus Infections
Puberty
Mexico
Developed Countries
Bone Marrow Cells
Developing Countries
Monocytes
Stem Cells
HIV
Newborn Infant
Morbidity

Keywords

  • Diagnosis
  • Human cytomegalovirus
  • Prophylaxis
  • Treatment

ASJC Scopus subject areas

  • Pharmacology
  • Virology

Cite this

De Jong, M. D., Galasso, G. J., Gazzard, B., Griffiths, P. D., Jabs, D., Kern, E. R., & Spector, S. A. (1998). Summary of the II International Symposium on Cytomegalovirus. Antiviral Research, 39(3), 141-162. https://doi.org/10.1016/S0166-3542(98)00044-8

Summary of the II International Symposium on Cytomegalovirus. / De Jong, Menno D.; Galasso, George J.; Gazzard, Brian; Griffiths, Paul D.; Jabs, Douglas; Kern, Earl R.; Spector, Stephen A.

In: Antiviral Research, Vol. 39, No. 3, 01.10.1998, p. 141-162.

Research output: Contribution to journalReview article

De Jong, MD, Galasso, GJ, Gazzard, B, Griffiths, PD, Jabs, D, Kern, ER & Spector, SA 1998, 'Summary of the II International Symposium on Cytomegalovirus', Antiviral Research, vol. 39, no. 3, pp. 141-162. https://doi.org/10.1016/S0166-3542(98)00044-8
De Jong MD, Galasso GJ, Gazzard B, Griffiths PD, Jabs D, Kern ER et al. Summary of the II International Symposium on Cytomegalovirus. Antiviral Research. 1998 Oct 1;39(3):141-162. https://doi.org/10.1016/S0166-3542(98)00044-8
De Jong, Menno D. ; Galasso, George J. ; Gazzard, Brian ; Griffiths, Paul D. ; Jabs, Douglas ; Kern, Earl R. ; Spector, Stephen A. / Summary of the II International Symposium on Cytomegalovirus. In: Antiviral Research. 1998 ; Vol. 39, No. 3. pp. 141-162.
@article{f33812993f2d4c86bdfc0f3a1481cc5e,
title = "Summary of the II International Symposium on Cytomegalovirus",
abstract = "Human cytomegalovirus (HCMV) is a highly species-specific DNA virus belonging to the Betaherpesvirinae subfamily of the herpesviridae family. Like other herpesviruses, primary infection with HCMV is followed by persistence of the virus in a latent form. The sites of latency are still largely undefined, but they probably include bone marrow progenitor cells and peripheral blood monocytes. From these sites, the virus can reactivate, resulting in renewed shedding of the virus, or, in immunocompromized persons, development of disease. Humans are the only reservoir of HCMV and transmission occurs by person-to-person contact. Infection with HCMV is common. In most developed countries, HCMV seroprevalence steadily increases after infancy and 10-20{\%} of children are infected before puberty. In adults, the prevalence of antibodies ranges from 40 to 100{\%}. Although HCMV has a world-wide distribution, infection with HCMV is more common in the developing countries and in areas of low socioeconomic conditions, which is predominantly related to the closeness of contacts within these populations. Except for a mononucleosis-like illness in some persons, infection with HCMV rarely causes disease in immunocompetent individuals. However, HCMV can cause severe morbidity and mortality in congenitally infected newborns and immunocompromized patients, most notably transplant-recipients and HIV-infected persons. This article provides a review of the information presented at the Second International Symposium on Cytomegalovirus organized and convened by The Macrae Group (New York City, NY) in Acapulco, Mexico on 24-28 April 1998. During this symposium, the state-of-the-art knowledge on diagnosis, treatment and prophylaxis of HCMV infections were discussed, and, based on this information, attempts to highlight the future directions in basic and clinical research areas that need to be stimulated to facilitate advancement in prevention and treatment of CMV disease. Copyright (C) 1998 Elsevier Science B.V.",
keywords = "Diagnosis, Human cytomegalovirus, Prophylaxis, Treatment",
author = "{De Jong}, {Menno D.} and Galasso, {George J.} and Brian Gazzard and Griffiths, {Paul D.} and Douglas Jabs and Kern, {Earl R.} and Spector, {Stephen A.}",
year = "1998",
month = "10",
day = "1",
doi = "10.1016/S0166-3542(98)00044-8",
language = "English (US)",
volume = "39",
pages = "141--162",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Summary of the II International Symposium on Cytomegalovirus

AU - De Jong, Menno D.

AU - Galasso, George J.

AU - Gazzard, Brian

AU - Griffiths, Paul D.

AU - Jabs, Douglas

AU - Kern, Earl R.

AU - Spector, Stephen A.

PY - 1998/10/1

Y1 - 1998/10/1

N2 - Human cytomegalovirus (HCMV) is a highly species-specific DNA virus belonging to the Betaherpesvirinae subfamily of the herpesviridae family. Like other herpesviruses, primary infection with HCMV is followed by persistence of the virus in a latent form. The sites of latency are still largely undefined, but they probably include bone marrow progenitor cells and peripheral blood monocytes. From these sites, the virus can reactivate, resulting in renewed shedding of the virus, or, in immunocompromized persons, development of disease. Humans are the only reservoir of HCMV and transmission occurs by person-to-person contact. Infection with HCMV is common. In most developed countries, HCMV seroprevalence steadily increases after infancy and 10-20% of children are infected before puberty. In adults, the prevalence of antibodies ranges from 40 to 100%. Although HCMV has a world-wide distribution, infection with HCMV is more common in the developing countries and in areas of low socioeconomic conditions, which is predominantly related to the closeness of contacts within these populations. Except for a mononucleosis-like illness in some persons, infection with HCMV rarely causes disease in immunocompetent individuals. However, HCMV can cause severe morbidity and mortality in congenitally infected newborns and immunocompromized patients, most notably transplant-recipients and HIV-infected persons. This article provides a review of the information presented at the Second International Symposium on Cytomegalovirus organized and convened by The Macrae Group (New York City, NY) in Acapulco, Mexico on 24-28 April 1998. During this symposium, the state-of-the-art knowledge on diagnosis, treatment and prophylaxis of HCMV infections were discussed, and, based on this information, attempts to highlight the future directions in basic and clinical research areas that need to be stimulated to facilitate advancement in prevention and treatment of CMV disease. Copyright (C) 1998 Elsevier Science B.V.

AB - Human cytomegalovirus (HCMV) is a highly species-specific DNA virus belonging to the Betaherpesvirinae subfamily of the herpesviridae family. Like other herpesviruses, primary infection with HCMV is followed by persistence of the virus in a latent form. The sites of latency are still largely undefined, but they probably include bone marrow progenitor cells and peripheral blood monocytes. From these sites, the virus can reactivate, resulting in renewed shedding of the virus, or, in immunocompromized persons, development of disease. Humans are the only reservoir of HCMV and transmission occurs by person-to-person contact. Infection with HCMV is common. In most developed countries, HCMV seroprevalence steadily increases after infancy and 10-20% of children are infected before puberty. In adults, the prevalence of antibodies ranges from 40 to 100%. Although HCMV has a world-wide distribution, infection with HCMV is more common in the developing countries and in areas of low socioeconomic conditions, which is predominantly related to the closeness of contacts within these populations. Except for a mononucleosis-like illness in some persons, infection with HCMV rarely causes disease in immunocompetent individuals. However, HCMV can cause severe morbidity and mortality in congenitally infected newborns and immunocompromized patients, most notably transplant-recipients and HIV-infected persons. This article provides a review of the information presented at the Second International Symposium on Cytomegalovirus organized and convened by The Macrae Group (New York City, NY) in Acapulco, Mexico on 24-28 April 1998. During this symposium, the state-of-the-art knowledge on diagnosis, treatment and prophylaxis of HCMV infections were discussed, and, based on this information, attempts to highlight the future directions in basic and clinical research areas that need to be stimulated to facilitate advancement in prevention and treatment of CMV disease. Copyright (C) 1998 Elsevier Science B.V.

KW - Diagnosis

KW - Human cytomegalovirus

KW - Prophylaxis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0032192290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032192290&partnerID=8YFLogxK

U2 - 10.1016/S0166-3542(98)00044-8

DO - 10.1016/S0166-3542(98)00044-8

M3 - Review article

C2 - 9833956

AN - SCOPUS:0032192290

VL - 39

SP - 141

EP - 162

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 3

ER -